Abstract
Vascular endothelial growth factor (VEGF) is an important mediator of normal and pathologic angiogenesis. Anti-VEGF therapy such as bevacizumab (BV) has shown promise in the treatment of recurrent glioblastoma multiforme and other solid tumors. It is recommended that BV therapy should be stopped at least 4 weeks before surgery to avoid complications. We present a patient with multifocal intracerebral hemorrhages after surgery for recurrent glioblastoma multiforme. His course of BV was temporarily ceased 6 weeks before repeat surgery. Our experience indicates that the anti-VEGF actions of BV can persist for longer than 6 weeks, with the potential consequence of hemorrhagic CNS complications.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
